Related Experiment Video
Updated: Nov 22, 2025

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
In-vivo imaging for assessing tumor growth in mouse models of ocular melanoma
Ortal Zaks1, Dimitri Gaber1, Keren Ben-Yaakov2
1Faculty of Medicine, The Hebrew University of Jerusalem, Department of Ophthalmology, Kaplan Medical Center, Israel; Ophthalmology Research Laboratory, Kaplan Medical Center, Rehovot, Israel.
Abstract:
Uveal melanoma (UM) and conjunctival melanoma (CM) are ocular malignancies that give rise to life-threatening metastases. Although local disease can often be treated successfully, it is often associated with significant vision impairment and treatments are often not effective against metastatic disease. Novel treatment modalities that preserve vision may enable elimination of small tumors and may prevent subsequent metastatic spread. Very few mouse models of metastatic CM and UM are available for research and for development of novel therapies. One of the challenges is to follow tumor growth in-vivo and to determine the right size for treatment, mainly of the posterior, choroidal melanoma. Hence, the purpose of this study was to establish a simple, noninvasive imaging tool that will simplify visualization and tumor follow-up in mouse models of CM and UM. Tumors were induced by inoculation of murine B16LS9 cells into the sub-conjunctival or the choroidal space of a C57BL/6 mouse eye under a surgical microscope. Five to ten days following injection, tumor size was assessed by Phoenix MicronIV™ image-guided Optical Coherence Tomography (OCT) imaging, which included a real-time camera view and OCT scan of the conjunctiva and the retina. In addition, tumor size was evaluated by ultrasound and histopathological examination of eye sections. Tumor growth was observed 5-9 days following sub-conjunctival or sub-retinal injection of seven-thousand or seventy-thousand cells, respectively. A clear tumor mass was detected at these regions using the MicronIV™ imaging system camera and OCT scans. Histology of eye sections confirmed the presence of tumor tissue. OCT allowed an accurate measurement of tumor size in the UM model and a qualitative assessment of tumor size in the CM model. Moreover, OCT enabled assessing the success rate of the choroidal tumor induction and importantly, predicted final tumor size already on the day of cell inoculation. In conclusion, by using a simple, non-invasive imaging tool, we were able to follow intraocular tumor growth of both CM and UM, and to define, already at the time of cell inoculation, a grading scale to evaluate tumor size. This tool may be utilized for evaluation of new mouse models for CM and UM, as well as for testing new therapies for these diseases.
Insights
Researchers developed a non-invasive Optical Coherence Tomography (OCT) imaging tool to track ocular melanoma growth in mouse models. This method aids in early tumor assessment and therapy evaluation for uveal melanoma (UM) and conjunctival melanoma (CM).
Area of Science:
- Ophthalmology
- Oncology
- Medical Imaging
Background:
- Uveal melanoma (UM) and conjunctival melanoma (CM) are aggressive eye cancers with high metastatic potential.
- Current treatments for ocular melanoma often result in vision loss and are ineffective against metastatic disease.
- Limited availability of mouse models hinders research and development of novel therapies for metastatic UM and CM.
Purpose of the Study:
- To establish a simple, non-invasive imaging tool for visualizing and monitoring tumor growth in ocular melanoma mouse models.
- To facilitate the evaluation of new therapeutic strategies and the development of improved preclinical models for UM and CM.
Main Methods:
- Murine B16LS9 melanoma cells were inoculated into the sub-conjunctival or choroidal space of C57BL/6 mouse eyes.
- Tumor growth and size were assessed using Phoenix MicronIV™ Optical Coherence Tomography (OCT) imaging, ultrasound, and histopathology.
- OCT imaging provided real-time visualization, cross-sectional scans, and quantitative tumor measurements.
Main Results:
- Tumor growth was observable 5-9 days post-injection in both conjunctival and choroidal models.
- OCT successfully visualized tumor masses and accurately measured tumor size in the uveal melanoma model.
- OCT enabled early prediction of tumor size and assessment of choroidal tumor induction success.
Conclusions:
- A non-invasive OCT imaging tool effectively monitors intraocular tumor growth in CM and UM mouse models.
- This imaging method allows for early grading of tumor size at the time of cell inoculation.
- The developed tool is valuable for evaluating new mouse models and testing novel therapies for ocular melanomas.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
07:46In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
Published on: August 17, 2010